Research
Hormonal
Statins are the first-choice pharmacological treatment for lowering LDL-C, non-HDL-C, and apo B, but they only marginally lower triglycerides and do not fully correct the dyslipidemia characteristic of obesity.
Statins are the primary medication for lowering bad cholesterol (LDL) and are recommended for obese patients with high cardiovascular risk. However, they do not significantly lower triglycerides, which are often elevated in obesity, so lifestyle changes remain crucial.
StrongQualifiesVERY_HIGH confidence
Statins are the first choice drug of all pharmacological agents to reduce LDL-C, non-HDL-C and/or apo B. However, statins lower TG only marginally and do not fully correct the characteristic dyslipidemia seen in obesity, which may contribute to the residual risk after initiating statin therapy [145].
Why this rating
This is a summary of clinical guidelines and meta-analyses cited in the review, representing high-level evidence consensus.
Source
Dyslipidemia in Obesity: Mechanisms and Potential Targets
Boudewijn Klop et al. · Nutrients · 2013
DOI 10.3390/nu5041218
narrative_reviewCited 1,656×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weight loss of 4–10 kg in obese subjects significantly reduces LDL-C by approximately 12% and increases LDL receptor mRNA levels by 27%.Good
- Dietary fat type influences postprandial lipemia, with diets high in saturated fatty acids (SFA) reducing lipoprotein lipase (LPL) activity in skeletal muscle and favoring lipid shunting to adipose tissue, whereas diets high in monounsaturated fatty acids (MUFA) reduce postprandial TG levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →